Enzo Biochem (ENZ) Stock Forecast, Price & News

Enzo Biochem's stock was trading at $1.43 at the beginning of the year. Since then, ENZ shares have increased by 53.8% and is now trading at $2.20.
View the best growth stocks for 2023 here.

Enzo Biochem saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the April 15th total of 1,120,000 shares. Based on an average trading volume of 849,700 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the shares of the company are sold short.
View Enzo Biochem's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 8th 2023.
View our ENZ earnings forecast.

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings data on Monday, March, 20th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter. The medical research company had revenue of $16.34 million for the quarter. Enzo Biochem had a negative net margin of 43.44% and a negative trailing twelve-month return on equity of 67.73%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Enzo Biochem's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.58%), Dimensional Fund Advisors LP (3.06%), BlackRock Inc. (2.86%), Roumell Asset Management LLC (1.82%), Potomac Capital Management Inc. (1.57%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, James G Wolf and Kara Cannon.
View institutional ownership trends.

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENZ stock can currently be purchased for approximately $2.20.

Enzo Biochem (NYSE:ENZ) has a market capitalization of $109.25 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

The company employs 451 workers across the globe.

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.